Rolls-Royce Engineering Lead Jonathan Simms talks about engineering the Ghost.
Rolls-Royce Engineering Lead Jonathan Simms talks about engineering the Ghost.
While it’s not quite Super Bowl levels, the secondary market prices for the Brady-Belichick reunion is already unprecedented for a regular-season game.
The National Stock Exchange of India is suing the country's market regulator to get access to 60 billion rupees ($816.77 million) of its revenue deposited into a separate account for over four years, the Economic Times reported https://economictimes.indiatimes.com/markets/stocks/news/nse-approaches-sat-to-access-over-6000-cr/articleshow/82619623.cms on Friday, citing people with knowledge of the matter. In September 2016, the Securities and Exchange Board of India (SEBI) had asked the NSE to deposit revenue generated from offering co-location services into a separate account and had barred it from using those funds, the report said. In April 2019, SEBI said https://www.reuters.com/article/india-sebi-nse-idUSL3N22C416 it did not have enough evidence that the NSE committed a fraudulent and unfair trade practice but it had established the exchange did not exercise due diligence when putting in place the co-location servers.
A former Army Green Beret who admitted divulging military secrets to Russia over a 15-year period is scheduled to be sentenced on espionage charges. Peter Dzibinski Debbins, 46, of Gainesville, Virginia, pleaded guilty in November to a federal Espionage Act charge in U.S. District Court in Alexandria. Debbins' relationship with Russian intelligence dates to 1996 and spanned 15 years.
The PA news agency looks at some of the key players for either side.
Joining us for today's call are AudioEye's interim CEO, Mr. David Moradi; executive chairman, Dr. Carr Bettis; and CFO, Mr. Before I turn the call over to AudioEye's executive chairman, the company would like to remind all participants that statements made by AudioEye management during the course of this conference call that are not historical facts are considered to be forward-looking statements.
Joining me on the call are Dr. Harry Stylli, chairman and chief executive officer; and Eric d'Esparbes, chief financial officer. Before I turn the call over to Dr. Stylli, I would like to remind you that today's call will include forward-looking statements within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our quarterly report on Form 10-Q that we will file later today and our subsequent periodic reports filed with the SEC, which will all be available on our website in the investor section.
Good afternoon, everyone, and thank you again for joining us in the StoneMor, Inc. conference call to discuss our 2021 first-quarter financial results. With us on the call this afternoon are Joe Redling, president and chief executive officer; and Jeffrey DiGiovanni, senior vice president and chief financial officer.
Kiawah Island will play to a maximum of 7,876 yards.
Image source: The Motley Fool. Vivint Smart Home, Inc. (NYSE: VVNT)Q1 2021 Earnings CallMay 13, 2021, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and thank you for standing by.
The Blues take on Barcelona in Gothenburg on Sunday.
The Blues will be looking to take step three of their quadruple bid in Gothenburg on Sunday.
Workers need time off to stay happy and engaged with their work – denying them this can seriously backfire for businesses.
PRESS RELEASE Regulated Information 14 May 2021, 7:00am, Antwerp (Berchem), Belgium: VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, today published a trading update for the first four months of 2021: Continued strong operating performance €12.5 million signed and renewed lease agreements, bringing total annualized rental income to €196.8 million (+6% year-to-date)A record 1,041,000 m2 under construction representing €64.8 million in additional annual rent once fully built and let (currently 80.1% pre-let)Completed portfolio grown with 58k m2 to 2.50 million m2 which is 99.6% let Expansion of land bank to secure future growth Extended pipeline through 471,000 m2 of new land bought and a further 3.1 million m2 committed subject to permitsTotal land bank acquired and secured has grown to 8.54 million m2 (+11.6% year-to-date) which supports 4.0 million m2 of future lettable area Joint Venture closing anticipated for end of May with expected net cash proceeds of €52 million Advanced discussions with Allianz regarding expansion of first Joint Venture ongoing VGP’s Chief Executive Officer, Jan Van Geet, said: “The year 2021 has started on a strong footing as demand for premium locations remains at elevated levels due to changing consumer behaviour and technological advancements in industry. Year-to-date we have signed €12.5 million of lease agreements and we expect this number to grow in the coming weeks as several signed prelim agreements representing >€10 million are expected to be finalized.” Jan Van Geet continued: "As a result, our predominantly pre-let construction portfolio is topping for the first time 1 million m2, of which over half is situated in Germany (with 215k in VGP Park München) and the other projects well spread across the other European markets. These strong market fundamentals and our resilient delivery put us at pace for another very strong year.” Jan Van Geet concluded: “Our recent inaugural €600 million international green bond offering has allowed us to diversify our funding mix and provides enhanced flexibility for future capital allocation decisions. Whilst maintaining a disciplined and fortress balance sheet, we remain committed to using our resources to drive inclusive and sustainable solutions for the communities we serve as we support our customers in solving their logistics needs or manufacturing real estate requirements. This has enabled us, despite scarcity of permittable land, to continue to make significant investments in the future pipeline, by replenishing and growing our secured land bank with net 900,000 m2 year to date, including several trophy locations which will drive leasing growth in the coming years.” OPERATING HIGHLIGHTS – 4M 2021 Lease operations Signed and renewed rental income of € 12.5 million driven by €11.8 million of new leases (€2.6 million on behalf of the Joint Ventures1) and €0.7 million of renewals (all on behalf of the Joint Ventures). Lease agreements in the amount of € 0.2 million were terminatedAnnualized committed leases at April 2021 (including Joint Ventures at 100%) of €196.8 million (vs €185.2 million at Dec-20) of which €145.9 million related to the Joint VenturesSeveral leasing contracts are in the pipeline and expected to be signed in the coming weeksThe impact of COVID-19 on leasing operations and customer payment behaviour has been minimal with virtually all rent payments received on time Development activities Development of 39 projects under construction totalling 1,041,000 m2 of future lettable area and expected to generate € 64.8 million of new rent when fully built and leased (80.1% pre-let)Geographical split of parks under construction: 53% is located in Germany, 11% Spain, 7% in each Czech Republic and Slovakia, 5% Romania, 4% in each Italy and Netherlands, 3% in each Hungary and Portugal and 1% in AustriaDelivery of 4 projects during the first four months of 2021 of in total 58,000 m2 of lettable area representing € 1.2 million of annualized committed leases; these buildings are 100% letAll construction activities currently run on schedule whilst taking into account the applicable Health and Safety guidance and regulations for all our operations in relation to COVID-19 Land bank During the first four months of 2021 in total 0.47 million m2 of land was acquired representing a development potential of 0.20 million m2A further 3.09 million m2 of land plots are committed, pending permits, and have a development potential of 1.31 million m2 of future lettable area, bringing the total owned and secured land bank to 8.54 million m2 supporting 3.97 million m2 of future lettable areaIn addition 3.83 million m2 of land has been identified and is under exclusive negotiation (representing 1.58 million m2 of future lettable area) Renewable Energy A total solar power generation capacity of 48.8MWp is currently installed or under construction through 45 roof-projects. This is being realised through a €21 million investment to date. In addition, the pipeline identified at the moment equates to an additional power generation capacity of 64 MWp Capital and liquidity position On 31 March 2021, VGP announced the successful issue of a first benchmark international green bond for an aggregate nominal amount of € 600 million, paying a coupon of 1.50 per cent. p.a. and maturing on 8 April 2029. Demand exceeded 2.7 times the volume of the issue. The proceeds from this issuance are being used to fund the majority pre-let development pipeline, the build out of renewable energy assets and the design and development of new green logistics and semi-industrial parksBefore the end of May, we anticipate the eighth closing with VGP European Logistics, the First Joint Venture with Allianz Real Estate. The expected transaction value is €70 million and the expected net cash proceeds amount to €52 million. As the First Joint Venture has reached its expanded investment target, this will be the last closing with the First Joint Venture to include new parks.Advanced discussion with Allianz Real Estate with regards to the expansion of the First Joint Venture are progressing well and expected to be finalized in the coming weeksOn 14 May 2021, the Board of Directors will propose to the Annual Shareholders Meeting to distribute a gross dividend of €3.65 per share corresponding to a total gross dividend amount of €75.1 million, with payment date proposed for 25 May 2021 (to be confirmed by shareholders at the AGM) CONTACT DETAILS FOR INVESTORS AND MEDIA ENQUIRIES Martijn Vlutters (VP – Business Development & Investor Relations)Tel: +32 (0)3 289 1433Petra Vanclova (External Communications)Tel: +42 0 602 262 107Anette NachbarBrunswick GroupTel: +49 152 288 10363 FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements. Such statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. VGP is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release in light of new information, future events or otherwise. The information in this announcement does not constitute an offer to sell or an invitation to buy securities in VGP or an invitation or inducement to engage in any other investment activities. VGP disclaims any liability for statements made or published by third parties and does not undertake any obligation to correct inaccurate data, information, conclusions or opinions published by third parties in relation to this or any other press release issued by VGP. ABOUT VGP VGP is a pan-European developer, manager and owner of high-quality logistics and semi-industrial real estate. VGP operates a fully integrated business model with capabilities and longstanding expertise across the value chain. The company has a development land bank (owned or committed) of 8.54 million m² and the strategic focus is on the development of business parks. Founded in 1998 as a Belgian family-owned real estate developer in the Czech Republic, VGP with a staff of c. 300 employees today owns and operates assets in 11 European countries directly and through several 50:50 joint ventures. As of December 2020, the Gross Asset Value of VGP, including the joint ventures at 100%, amounted to € 3.84 billion and the company had a Net Asset Value (EPRA NAV) of € 1.35 billion. VGP is listed on Euronext Brussels and on the Prague Stock Exchange (ISIN: BE0003878957). For more information, please visit: http://www.vgpparks.eu 1 Joint Ventures means either and each of (i) the First Joint Venture i.e. VGP European Logistics S.à.r.l., the 50:50 joint venture between VGP and Allianz and (ii) the Second Joint Venture i.e. VGP European Logistics 2 S.à.r.l., the 50:50 joint venture between VGP and Allianz, and (iii) the Third Joint Venture i.e. VGP Park München GmbH, the 50:50 joint venture between VGP and Allianz, and (iv) LPM Joint Venture, i.e. LPM Holding B.V., the 50:50 joint venture between VGP and Roozen Landgoederen Beheer Attachment VGP - Trading update - 14 May 2021 (EN)
England’s World Cup-winning captain saw his Leicester team beaten 39-14 by Wasps in the Premiership final.
Capsule, the online CRM, has launched an integration with Microsoft 365 (M365), enhancing its platform with a new Microsoft Outlook add-in, Calendar integration, and Single Sign-On.
ReGenTree, LLC ('Company'), a U.S. joint venture company between GtreeBNT and RegeneRx, announced results of additional analysis of the Phase 3 clinical trial, ARISE-3, using RGN-259 for the treatment of dry eye syndrome. The Company also pooled data from all three Phase 3 clinical trials for dry eye.
Sogou Inc. (NYSE: SOGO) ("Sogou" or the "Company"), an innovator in search and a leader in China's internet industry, today announced its unaudited financial results for the first quarter, ended March 31, 2021.
Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan’s Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG) Management to host conference call today at 2:30 pm CEST (8:30 am ET) May 14, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today reported financial results for the first quarter 2021 and provided a business update. “We’ve had a strong start to 2021 with the acceptance for review of the BLA and J-MAA for efgartigimod in gMG by the regulatory agencies in the U.S. and Japan. The submissions in China and the EU are on track and we are well-positioned for a global launch of our first-in-class FcRn antagonist. We are building an exceptional team with significant launch experience in neurology and rare disease and hope to reach patients this year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “Efgartigimod has the potential to help people living with gMG as well as several other severe autoimmune diseases mediated by IgG autoantibodies. Our team is advancing registrational trials across four indications with plans to start enrollment in two additional efgartigimod indications this year. We are also broadening our reach within autoimmunity with our first-in-class C2 inhibitor, ARGX-117, from which we will have Phase 1 data mid-year. To complement our clinical pipeline, we continue to invest in our discovery capabilities through our Immunology Innovation Program and strategic technology partnerships that position us well to generate long-term value for shareholders. We are closer each day to building an integrated, innovative, global immunology organization with the goal of impacting the lives of patients,” concluded Mr. Van Hauwermeiren. FIRST QUARTER 2021 AND RECENT BUSINESS UPDATE Commercial preparations on-track for global launch of IV efgartigimod for gMG, including regulatory submissions, initial salesforce hires and key stakeholder engagement efforts Biologics License Application (BLA) for IV efgartigimod for treatment of gMG accepted for review by U.S. Food and Drug Administration (FDA) with target action date of December 17, 2021 under Prescription Drug User Fee Act (PDUFA)J-MAA submitted to Japan’s PMDA and accepted for review with anticipated Japan commercial launch in 2022MAA expected to be filed with European Medicines Agency (EMA) in second half of 2021Zai Lab Limited to discuss potential accelerated regulatory pathway for approval in China with National Medical Products Administration (NMPA)Commercial readiness activities on-track, including: Continued build-out of global commercial organization, including hiring of U.S. regional business directors during first quarterLaunched pre-approval access (PAA) program in March 2021 in U.S., Canada and Europe to open availability of efgartigimod to people living with gMG who meet the pre-approval access program criteria Immunology pipeline advancing with five ongoing registrational trials of efgartigimod and initial upcoming data from second potential pipeline-in a product candidate, ARGX-117 Enrollment ongoing in five registrational trials across four indications, including ADAPT-SC (gMG), ADHERE (chronic inflammatory demyelinating polyneuropathy or CIDP), ADVANCE and ADVANCE-SC (primary immune thrombocytopenia or ITP), and ADDRESS (pemphigus) Go-forward decision confirmed in February 2021 in ADHERE trial evaluating subcutaneous (SC) efgartigimod in CIDP based on evaluation of interim safety and efficacy assessments that surpassed pre-defined thresholdEnrollment in trials for fifth and sixth indications to begin in 2021Additional efgartigimod indications to be evaluated as part of collaboration with Zai Lab Limited Data expected mid-year from Phase 1 trial of C2 inhibitor, ARGX-117; Phase 2 dosing plan to be identified for indications, including multifocal motor neuropathy (MMN) Phase 2 trial of MMN on track to start by end of 2021 Combination trials of cusatuzumab remain ongoing for treatment of acute myeloid leukemia (AML) as part of global collaboration and licensing agreement with Cilag GmbH International, an affiliate of Janssen Decision to initiate additional cusatuzumab studies under collaboration will be determined following review of all available data Immunology Innovation Program (IIP) continues to grow pipeline through wholly-owned development, partnered opportunities, asset-centric spinoff companies and the addition of strategic technology capabilities Preclinical work ongoing in early-stage pipeline, including ARGX-118, ARGX-119 and ARGX-12015-20 discovery programs under evaluation at any point in time that have emerged from IIPInitiated collaboration and license agreement with Elektrofi to explore new subcutaneous formulations for current and future pipeline candidates, including efgartigimod Secured exclusivity for FcRn and one additional target Ongoing development of ARGX-112 (LEO Pharma), ARGX-114 (AgomAb), ARGX-115 (ABBV-151, AbbVie) and ARGX-116 (Staten Biotech) by IIP collaboration partners Strong balance sheet and expanded Board of Directors support transition into integrated, global immunology organization Completed public offering of 3,593,750 ordinary shares in February 2021 with gross proceeds of $1.15 billionImplemented transition agreement for Chief Financial Officer Eric Castaldi as part of evolution to commercial-stage company; recruitment efforts ongoing for U.S.-based successorProposed resolutions presented during Annual General Meeting of Shareholders were approved, including: Appointment to Board of Directors of Yvonne Greenstreet, President and Chief Operating Officer of AlnylamRe-appointment of Anthony Rosenberg to Board of DirectorsApproval of new remuneration policy argenx to host virtual R&D Day on July 20, 2021 to share long-term corporate vision, disclose additional potential efgartigimod indications and provide updates across immunology pipeline. FIRST QUARTER 2021 FINANCIAL RESULTS (CONSOLIDATED) Three Months Ended March 31, (in thousands of $ except for shares and EPS) 2021 2020 VarianceRevenue $158,155 $21,139 $137,017Other operating income 9,260 4,672 4,588Total operating income 167,415 25,811 141,604 Research and development expenses (122,328) (104,661) (17,666)Selling, general and administrative expenses (56,253) (27,609) (28,644)Total operating expenses (178,580) (132,270) (46,310)Change in fair value on non-current financial assets 11,152 0 11,152Operating loss $(13) $(106,459) $106,446 Financial income/(expenses) (420) (3,591) 3,171Exchange gain/(losses) (28,817) 22,985 (51,802)Loss before taxes $(29,249) $(87,064) $57,815 Income taxes (11,184) (1,200) (9,984)Loss for the period and total comprehensive loss $(40,433) $(88,264) $47,831 Weighted average number of shares outstanding 49,946,515 42,786,194 Basic and diluted profit/(loss) per share (in $) (0.81) (2.06) Net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2020 and 2019 910,903 (70,318) Cash, cash equivalents and current financial assets at the end of the period 2,907,355 1,430,343 DETAILS OF THE FINANCIAL RESULTS As of January 1, 2021, the Company changed its functional and presentation currency from euro to U.S. dollars, which results in reporting its financial highlights in U.S. dollar as compared to euro in prior periods. Historical financials have been converted at the average exchange rate of the related period. Cash, cash equivalents and current financial assets totaled $2,907.4 million on March 31, 2021, compared to $1,996.5 million on December 31, 2020. The increase in cash, cash equivalents and current financial assets resulted primarily from (i) the closing of a global offering, which resulted in the receipt of $1,092.1 million in net proceeds in February 2021, (ii) the net receipt of a $73.1 million non-creditable, non-refundable development cost-sharing payment in the form of newly issued Zai Lab shares received as part of the strategic collaboration for efgartigimod in Greater China, partially offset by (iii) the payment of $98.0 million related to the purchase of a priority review voucher from Bayer HealthCare Pharmaceuticals and other net cash flows used in operating activities. Total operating income increased by $141.6 million for the three months ended March 31, 2021 to $167.4 million, compared to $25.8 million for the three months ended March 31, 2020. The increase was primarily due to the closing of the strategic collaboration for efgartigimod with Zai Lab, resulting in the recognition of $151.9 million in collaboration revenue. Research and development expenses increased by $17.7 million for the three months ended March 31, 2021 to $122.3 million, compared to $104.7 million for the three months ended March 31, 2020. The increase in the first three months of 2021 resulted primarily from higher external research and development expenses, mainly related to the efgartigimod program in multiple indications and other clinical and preclinical programs. Furthermore, the research and development personnel expenses increased due to a planned increase in headcount and the increased costs of the share-based payment compensation plans related to the grant of stock options. Selling, general and administrative expenses totaled $56.3 million for the three months ended March 31, 2021, compared to $27.6 million for the three months ended March 31, 2020. The increase resulted primarily from higher personnel expenses, including the costs of the share-based payment compensation plans related to the grant of stock options, and consulting fees linked to the preparation of a possible future commercialization of efgartigimod. The increase in fair value on non-current financial assets amounted to $11.2 million for the three months ended March 31, 2021, which is the result of the closing of a Series B financing round of AgomAb Therapeutics, for which the Company maintains a profit share in exchange for granting the license for the use of HGF-mimetic antibodies from the SIMPLE Antibody™ platform. Exchange losses totaled $28.8 million for the three months ended March 31, 2021, compared to an exchange gain of $23.0 million for the three months ended March 31, 2020. As a result of the change in the Company’s functional and presentation currency, the exchange losses for the three months ended March 31, 2021 are reflecting the unfavorable change in euro/U.S. dollar exchange rate, mainly attributable to unrealized exchange rate losses on cash, cash equivalents and current financial asset position in euro. FINANCIAL GUIDANCE Based on current plans to fund anticipated operating expenses and capital expenditures, argenx continues to expect its 2021 cash burn to approximately double from 2020. The increased spend will support the Company’s transition to an integrated immunology company, including the build-out of global commercial infrastructure and drug product inventory ahead of the expected launch of efgartigimod in gMG in the U.S, the advancement of its clinical-stage pipeline, including seven expected global trials of efgartigimod, and the continued investment in its Immunology Innovation Program. EXPECTED 2021 FINANCIAL CALENDAR July 29, 2021: HY 2021 financial results and business updateOctober 28, 2021: Q3 2021 financial results and business update CONFERENCE CALL DETAILSThe first quarter 2021 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 pm CEST/8:30 am ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website. Dial-in numbers:Please dial in 15 minutes prior to the live call. Belgium 0800 389 13 France 0805 102 319 Netherlands 0800 949 4506 United Kingdom 0800 279 9489 United States 1 844 808 7140International 1 412 902 0128 About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal. For further information, please contact: Media:Kelsey KirkKKirk@argenx.com Joke Comijn (EU)firstname.lastname@example.org Investors:Beth DelGiaccobdelgiacco@argenx.com Michelle Greenblattmgreenblatt@argenx.com Forward-looking Statements The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” or “should” and include statements argenx makes concerning its statement that the submissions in China and the EU are on track and that it is well-positioned for a global launch of its first-in-class FcRn antagonist, including that BLA for IV efgartigimod for treatment of gMG accepted for review by the U.S. Food and Drug Administration (FDA) in March 2021 with target action date of December 17, 2021 under Prescription Drug User Fee Act (PDUFA), J-MAA submitted to Japan’s PMDA and accepted for review with anticipated Japan commercial launch in 2022, MAA expected to be filed with European Medicines Agency (EMA) in second half of 2021 and Zai Lab Limited to discuss potential accelerated regulatory pathway for approval in China with National Medical Products Administration (NMPA); statements regarding its commercial readiness; its statement that enrollment in trials for fifth and sixth indications to begin in 2021; its statement that data expected mid-year from Phase 1 trial of C2 inhibitor, ARGX-117; Phase 2 dosing plan to be identified for indications including multifocal motor neuropathy (MMN), and Phase 2 trial of MMN on track to start by end of 2021; its expectation that its 2021 cash burn will approximately double from 2020; its hope to reach patients this year; its statements regarding the therapeutic potential of Efgartigimod in patients with gMG as well as several other severe autoimmune diseases mediated by IgG autoantibodies; its plans to start enrollment in two additional efgartigimod indications this year, its expectation to have Phase 1 data mid-year for its C2 inhibitor, ARGX-117, 2021 business and financial outlook and related plans; the therapeutic potential of its product candidates; the intended results of its strategy and argenx’s, and its collaboration partners’, advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including the effects of the COVID-19 pandemic, argenx’s expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx’s reliance on collaborations with third parties; estimating the commercial potential of argenx’s product candidates; argenx’s ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx’s limited operating history; and argenx’s ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
Regulated Information Nyrstar NV 2020 Full Year Results 14 May 2021 at 07:00 CEST Nyrstar NV ("Nyrstar" or the “Company”) is today announcing the publication of its financial statements for the twelve months ended 31 December 2020 (“Full Year Results 2020”). The Full Year Results 2020 have been prepared on a discontinuity basis as a result of the decision of the extraordinary shareholders’ meeting of 9 December 2019 to reject the continuation of the Company’s activities. The Company has received from its auditor, and is publishing today, an audit opinion to accompany its Full Year Results 2020. In its audit opinion, the auditor confirms that in its opinion, the annual accounts give a true and fair view of the Company’s net equity and financial position as of 31 December 2020, in accordance with the financial reporting framework applicable in Belgium. The Full Year Results 2020 and the associated reports of the Company’s board of directors have today been published in the reports and presentation section of the Nyrstar website (see https://www.nyrstar.be/en/investors/results-reports-and-presentations/2021). About NyrstarThe Company is incorporated in Belgium and, following completion of the recapitalisation/restructuring has a 2% shareholding in the Nyrstar group. The Company is listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar website: www.nyrstar.be For further information contact: Anthony Simms - Head of External Affairs & Legal M: +41 79 722 2152 email@example.com Attachment FY 2020 Nyrstar results release EN
Sohu.com Limited (NASDAQ: SOHU), China's leading online media, video, gaming and search business group, today reported unaudited financial results for the first quarter ended March 31, 2021.